

IMMTECH PHARMACEUTICALS, INC.

Form 4

May 15, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SORKIN ERIC L

2. Issuer Name and Ticker or Trading Symbol  
IMMTECH PHARMACEUTICALS, INC. [IMM]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
ONE NORTH END DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
04/15/2006

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chairman, President and CEO

NEW YORK,, NY 10282

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| Common Stock, \$0.01 par value  | 04/15/2006                           |  | J <sup>(2)</sup>               | 342   | A 7.866 438,594 <sup>(4)</sup> <sup>(5)</sup>   | D  |                                   |
| Common Stock, \$0.01 par value  | 04/15/2006                           |  | J <sup>(3)</sup>               | 827   | A 7.866 438,594 <sup>(4)</sup> <sup>(5)</sup>   | D  |                                   |
| Common Stock, \$0.01 par value  | 10/15/2006                           |  | J <sup>(2)</sup>               | 510   | A 5.301 438,594 <sup>(4)</sup> <sup>(5)</sup>   | D  |                                   |

Edgar Filing: IMMTECH PHARMACEUTICALS, INC. - Form 4

|                                |            |                  |       |   |                           |                                       |   |
|--------------------------------|------------|------------------|-------|---|---------------------------|---------------------------------------|---|
| Common Stock, \$0.01 par value | 10/15/2006 | J <sup>(3)</sup> | 2,127 | A | \$<br>5.301<br><u>(1)</u> | 438,594 <sup>(4)</sup> <sup>(5)</sup> | D |
| Common Stock, \$0.01 par value | 04/15/2007 | J <sup>(2)</sup> | 410   | A | \$<br>6.567<br><u>(1)</u> | 438,594 <sup>(4)</sup> <sup>(5)</sup> | D |
| Common Stock, \$0.01 par value | 04/15/2007 | J <sup>(3)</sup> | 1,707 | A | \$<br>6.567<br><u>(1)</u> | 438,594 <sup>(4)</sup> <sup>(5)</sup> | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned (Instr. 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|  |  |                                      |  |                                |   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares                                       |
|  |  |                                      |  |                                |   | Code   | V (A) (D)   |  |  |

## Reporting Owners

| Reporting Owner Name / Address                              | Relationships |           |                             |       |
|---|---------------|-----------|-----------------------------|-------|
|   | Director      | 10% Owner | Officer                     | Other |
| SORKIN ERIC L<br>ONE NORTH END DRIVE<br>NEW YORK,, NY 10282 | X             |           | Chairman, President and CEO |       |

## Signatures

/s/ Eric L.  
Sorkin

05/15/2007

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The shares of common stock issued as a dividend was based upon the ten-day weighted average of the closing price of the Company's common stock.
- (2) Shares of common stock issued as dividend payment on Series A Preferred Stock.
- (3) Shares of common stock issued as dividend payment on Series E Preferred Stock.

(4) Includes (i) 62,735 shares of Common Stock, (ii) 20,362 shares of Common Stock issuable upon the conversion of Series A Convertible Preferred Stock, (iii) 53,267 shares of Common Stock issuable upon the conversion of Series E Convertible Preferred Stock, (iv) 217,500 shares of Common Stock issuable upon the exercise of warrants as follows: (a) vested warrant to purchase 36,923 shares of common stock at \$6.47 per share by July 24, 2008, (b) vested warrant to purchase 173,077 shares of Common Stock at \$6.47 per share by October 12, 2008 and (c) vested warrant to purchase 7,500 shares of Common Stock at \$10.00 per share by December 13, 2008 and (CONTINUED IN FOOTNOTE 5)

(5) (CONTINUED FROM FOOTNOTE 4) (v) 84,730 shares of Common Stock issuable upon the exercise of options as follows: (a) vested option to purchase 22,000 shares of Common Stock at \$14.29 per share by February 1, 2014, (b) vested option to purchase 972 shares of Common Stock at \$2.55 per share by December 24, 2007, (c) vested option to purchase 22,000 shares of Common Stock at \$11.03 per share by November 15, 2014, (d) vested portion of 14,758 shares of an option to purchase 20,834 shares of Common Stock at \$7.85 per share by January 24, 2016 (option vests in 24 equal monthly installments from date of grant) and (e) vested portion of 25,000 shares of an option to purchase 75,000 shares of Common Stock at \$5.74 per share by October 15, 2016 (option vests in 24 equal monthly installments from date of grant).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.